7 February 2019

Seyed Qaderi and Hans de Wilt together with the department of Surgical Oncology developed and implemented a new patient centered follow up schedule for colorectal cancer survivors.

After treatment, colorectal cancer patients remain under surveillance in the hospital for at least 5 years. This is performed according to the national guidelines.
The purpose of these appointments is to screen for symptoms and explore patient wellbeing, and to detect metastases or recurrent disease as early as possible.
Research demonstrates that periodic outpatient clinic visits are not always useful. It leads to long waiting times and it can lead to more (unnecessary) treatments, anxiety among patients and higher healthcare costs without improving patient survival.
Patient organizations and health professionals call for new patient-oriented follow up schedules. In these new schemes emphasis should be on quality of life, attention to the consequences of operative interventions on daily life, psychosocial wellbeing.
More involvement of patients in decision making and follow up improves the emotional and social well-being of patients and gives the patient more autonomy and (self-) confidence.
The follow up policy of colorectal cancer patients treated at Radboudumc has changed. After being followed, undergoing the necessary tests in the first year, patients do not longer have to come to the hospital for the results of the tests hereafter. The results will be made available through our electronic mijnRadboud platform in a patient-friendly manner. When experiencing symptoms, having questions, or noticing abnormal test results, patients are advised to call our nurse practitioner and when necessary, telephone, video-chat, or a physical clinical visit will be planned.
With adequate patient training and written information and instructions on what to do and when to do (self management), we aim at increasing patient involvement and satisfaction during bowel cancer follow up!
More information can be found (in Dutch): www.radboudumc.nl/darmkanker

 Seyed Qaderi and Hans de Wilt are both members of theme Tumors of digestive tract.

Related news items

Cognitive behavioral therapy reduces severe fatigue in patients with advanced cancer during treatment

28 January 2020

In Annals of Oncology, RIHS researchers Hanneke Poort, Marlies Peters, Winette van der Graaf, Ria Nijhuis van der Sanden and colleagues showed significant effects of cognitive behavioral therapy on fatigue in patients with advanced cancer during treatment with palliative intent.

read more

Prinses Beatrix Spierfonds grant to investigate patient stratification in myotonic dystrophy

24 January 2020

Rick Wansink and Roland Brock, both theme Nanomedicine, received a € 280,000 grant from the Prinses Beatrix Spierfonds.

read more

RIMLS PhD retreat registration is open

23 January 2020

Yearly, RIMLS PhD candidates gather for the two-day PhD Retreat. Apart from the science, this event is highly valued for the opportunity to meet and get to know fellow PhD candidates during the social activities. Early bird registration and abstract submission deadline: 4 March 2020.

read more

6 million euros to uncover link between metabolic and brain disorders

21 January 2020

An important European-funded initiative, coordinated by Radboudumc researchers Barbara Franke, Jan Buitelaar, and Janita Bralten, has been launched to explore how common molecular mechanisms may link metabolic disorders with brain disorders.

read more

NWO Open Competition Domain Science - XS grant for Ronald van Rij and Jenny van der Wijst

21 January 2020

NWO Domain Science has awarded Ronald van Rij, theme Infectious diseases and global health and Jennny van der Wijst, theme Renal disorders an XS grant. The XS category emphatically strives to encourage curiosity-driven and bold research involving a relatively quick analysis of a promising idea.

read more

First BeNeFit funding granted for psoriasis

17 January 2020

RIHS researchers Elke de Jong and Juul van den Reek of Dermatology Radboudumc and Dermatology Ghent received a grant of 1.6 million euros for investigating dose reduction of the newest biologics for psoriasis.

read more